We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New Method Helps To Advise on Medication Use While Breastfeeding

A person holding a baby.
Credit: Wes Hicks/Unsplash
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

It’s the start of World Breastfeeding Week, and University of Waterloo Pharmacy researchers have developed a novel metric for an underserved research area to aid healthcare providers in advising on maternal medication use for breastfeeding mothers or nursing persons.

Breastfeeding while taking medication is often questioned, with medical practitioners erring on the side of caution and advising breastfeeding mothers not to use medications. However, considerations of medication use while breastfeeding may stop the mother’s own important drug therapy or lead to the discontinuation of breastfeeding.

“The limited information on medication use during lactation has created a significant knowledge gap that directly impacts a vulnerable population due to the exclusion of lactating persons and infants from the drug development process,” said Dr. Cindy Yeung, lead author of a paper detailing the research and a recent PhD graduate.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Dr. Yeung and colleagues have developed a new metric using mathematical modelling to aid healthcare providers in medication prescribing for those who breastfeed their infants.

“We developed the novel Upper Area Under the Curve Ratio (UAR) metric using physiologically based pharmacokinetic (PBPK) modelling to help a population that is often left out of scientific research,” said Yeung.

PBPK modelling simulates a virtual person and represents how a drug moves in a body through mathematical functions. Through this modelling, researchers can understand how much of the drug is present in the breastmilk and whether it will be transferred to the infant.

The UAR metric incorporates major factors that the current metrics lack to define risk to the breastfeeding infant: the anatomy and physiology of the infant, age-related changes in breastmilk volume consumed and variability in infant exposure. One source of variability is pharmacogenotype – a genetic variant that may lead to an increased or decreased ability of the mother or infant to excrete the drug.

“The UAR metric uses an estimated drug dose from breastmilk that is then given to virtual infants to assess likely drug exposures and to identify characteristics of those infants that may be at increased risk to high exposures. This brings researchers one step closer to understanding the response or the adverse effects you might see in infants,” Yeung said.

By implementing the UAR metric into existing informational resources, healthcare providers will have more confidence to advise on maternal medication use informed by evidence, with the potential to directly impact the quality of life for the maternal-infant pair.

Reference: Yeung CHT, Houle SKD, Anderson PO, Best BM, Dubinsky S, Edginton AN. Addressing maternal medication use during breastfeeding using clinical resources and a novel physiologically based pharmacokinetic model-derived metric: A qualitative study. Front. Pediatr. 2023;11. 2023. doi: 10.3389/fped.2023.1147566

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.